Close Menu

NEW YORK (GenomeWeb) – UBS today initiated coverage of Agilent Technologies with a Buy rating and price target of $92; Fluidigm with a  Neutral rating and price target of $14; and Qiagen with a Neutral rating and price target of $42.

In a report to investors, UBS analyst Daniel Brennan noted that for Agilent, the investment bank's above-consensus 2019 through 2021 organic revenue forecasts are supported by durable high single-digit growth in pharma along with growth tied to the gas chromatography product cycle in the chemical and energy segment.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

In Science this week: whole-genome sequencing of single sperm cells, and more.

Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.